Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Recurrent Squamous Cell Lung Carcinoma × telisotuzumab vedotin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 4 Neoplasms 2 Recurrent Squamous Cell Lung Carcinoma 1 Neoplasm Metastasis 1

Interventions

tremelimumab 1 telisotuzumab vedotin 1 durvalumab 1 Immunoglobulin G 1 Disulfides 1 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03574753 2021-10-18

Lung-MAP S1400K: c-MET Positive

SWOG Cancer Research Network

Phase 2 Completed

28 enrolled 18 charts

Recurrent Squamous Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡